WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Search Results -

Term	Documents
LM609.DWPI,EPAB,JPAB.	4
LM609S	0
LM609.JPAB,EPAB,DWPI.	4

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search: lm609

Clear

Search History

Today's Date: 6/24/2001

DB Name	Query	Hit Count	Set Name
JPAB,EPAB,DWPI	lm609	4	L5
JPAB,EPAB,DWPI	lm609 same (humaniz$ or humanis$)	1	L4
USPT,PGPB	lm609 same (humaniz$ or humanis$)	2	L3
USPT,PGPB	lm609	34	L2
USPT,PGPB	lm609	34	L1

***Kompass Canada (File 594)

FILES REMOVED
***EconBase (File 565)

New pricing structure for Pharmaprojects (Files 128/928) from April 1, 2001. Check Help News128 or Help News928 for further information.

>>>Get immediate news with Dialog's First Release news service. First Release updates major newswire databases within 15 minutes of transmission over the wire. First Release provides full Dialog searchability and full-text features. To search First Release files in OneSearch simply BEGIN FIRST for coverage from Dialog's broad spectrum of news wires.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
>>> of new databases, price changes, etc. <<<
****

File 1:ERIC 1966-2001/Jun 05
(c) format only 2001 The Dialog Corporation

Set	Items	Description

? b 410

>>>'IALOG' not recognized as set or accession number
? set hi **;set hi**

24jun01 08:01:48 User208760 Session D1867.1
$0.41 0.116 DialUnits File1
$0.41 Estimated cost File1
$0.05 TYMNET
$0.46 Estimated cost this search
$0.46 Estimated total session cost 0.116 DialUnits

File 410:Chronolog(R) 1981-2001/May
(c) 2001 The Dialog Corporation

Set	Items	Description

?
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,155,399

24jun01 08:02:00 User208760 Session D1867.2
$0.00 0.056 DialUnits File410
$0.00 Estimated cost File410
$0.01 TYMNET
$0.01 Estimated cost this search
$0.47 Estimated total session cost 0.172 DialUnits

SYSTEM:OS - DIALOG OneSearch
File 5:Biosis Previews(R) 1969-2001/Jun W3
(c) 2001 BIOSIS
File 73:EMBASE 1974-2001/Jun W3

```
        (c) 2001 Elsevier Science B.V.
*File  73: For information about Explode feature please
see Help News73.
  File 155:MEDLINE(R)  1966-2001/Jun W4
        (c) format only 2001 Dialog Corporation
*File 155: This file has been reloaded. Accession numbers have changed.
 Please see Help News155 for further details.
  File 399:CA SEARCH(R)  1967-2001/UD=13426
        (c) 2001 AMERICAN CHEMICAL SOCIETY
*File 399: Use is subject to the terms of your user/customer agreement.
RANK charge added; see HELP RATES 399.

      Set  Items  Description
      ---  -----  -----------
? e au=huse william ?


Ref   Items  Index-term
E1        1  AU=HUSE WE
E2        3  AU=HUSE WILLIAM
E3        0 *AU=HUSE WILLIAM ?
E4       19  AU=HUSE WILLIAM D
E5        1  AU=HUSE WILLIAM DAVID
E6        1  AU=HUSE WILLIAM E
E7        7  AU=HUSE WM
E8        4  AU=HUSE Y
E9        2  AU=HUSE Y.
E10       6  AU=HUSE-BENDA A R
E11       3  AU=HUSE-BENDA A.R.
E12       4  AU=HUSE-BENDA AR

          Enter P or PAGE for more
? s e2-e5

               3  AU=HUSE WILLIAM
               0  AU=HUSE WILLIAM ?
              19  AU=HUSE WILLIAM D
               1  AU=HUSE WILLIAM DAVID
     S1       23  E2-E5
? s s1 and (lm609 or vitaxin)

              23  S1
             220  LM609
              57  VITAXIN
     S2        2  S1 AND (LM609 OR VITAXIN)
? rd s2

...completed examining records
     S3        2  RD S2 (unique items)
? t s3/7/all


 3/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

13078880   BIOSIS NO.: 200100286029
A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti
  alphavbeta3) antibody in patients with metastatic cancer.
AUTHOR: Posey James A(a); Khazaeli M B; DelGrosso Alma; Saleh Mansoor N;
  Lin Chin Yu; Huse William; LoBuglio Albert F
AUTHOR ADDRESS: (a)Division of Hematology/Oncology, University of Alabama
  at Birmingham, 1824 6th Avenue, South, 263 Wallace Tumor Institute,
  Birmingham, AL, 35294-3300: james.posey@ccc.uab.edu**USA
JOURNAL: Cancer Biotherapy & Radiopharmaceuticals  16 (2):p125-132 2001
MEDIUM: print
```

ISSN: 1084-9785
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: The angiogenic response of a progressing malignancy is characterized by a shift in the balance of stimulatory and inhibiting factors of angiogenesis. Recognition of the regulated steps in tumor angiogenesis provides unique targets for developing anti-tumor therapy. **Vitaxin** is a humanized monoclonal antibody, which has specificity for the integrin alpha v beta 3 (vitronectin receptor). This antibody can impair the vascular response of endothelial cell growth factors in vitro and inhibit tumor cell mediated angiogenesis in pre-clinical animal models. Patients with metastatic cancer who failed standard therapy received intravenous doses of 10, 50 or 200 mg in cohorts of three patients. The unlabeled dose of **Vitaxin** was infused on days 0 and 21 of a treatment cycle. All patients received a pre-therapy imaging dose of 1 mg of Tc-99m **Vitaxin** with gamma camera imaging studies. There was no significant toxicity noted in these three dose levels. There were no objective anti-tumor responses. Three patients received two cycles of therapy and had stable disease at day 85 when taken off study. Radioimaging of tumor vasculature was unsuccessful although one patient with alphavbeta3 positive melanoma had imaging of tumor sites. There was no immune response to **Vitaxin** in any patient. Patients receiving 10 mg doses of **Vitaxin** had poor plasma recovery of injected doses and brief circulation in plasma. Doses of 50 and 200 mg had plasma recovery that better approximated the predicted levels in plasma and circulation half-lives of approximately 7 days. This data suggests that an every three-week schedule of **Vitaxin** at doses of 200 mg (2.5 - 3.5 mg/kg) can maintain circulating levels of antibody with little or no toxicity. Future studies will be challenged to define anti-tumor activity in malignancy or appropriate surrogates of anti-tumor effect and explore escalating doses and alternate schedules of administration.

3/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11514991 BIOSIS NO.: 199800296323
Stepwise in vitro affinity maturation of **Vitaxin**, an alphavbeta3-specific humanized mAb.
AUTHOR: Wu Herren; Beuerlein Gregory; Nie Ying; Smith Heidi; Lee Bruce A; Hensler Mary; **Huse William D**; Watkins Jeffry D(a
AUTHOR ADDRESS: (a)Ixsys Inc., 3520 Dunhill St., San Diego, CA 92121**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 95 (11):p6037-6042 May 26, 1998
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: A protein engineering strategy based on efficient and focused mutagenesis implemented by codon-based mutagenesis was developed. **Vitaxin**, a humanized version of the antiangiogenic antibody **LM609** directed against a conformational epitope of the alphavbeta3 integrin complex, was used as a model system. Specifically, focused mutagenesis was used in a stepwise fashion to rapidly improve the affinity of the antigen binding fragment by greater than 90-fold. In the complete absence of structural information about the Vitaxinalphavbeta3 interaction, phage-expressed antibody libraries for all six Ig heavy and light chain complementarity-determining regions were expressed and screened by a quantitative assay to identify variants with improved binding to alphavbeta3. The **Vitaxin** variants in these libraries each contained a single mutation, and all 20 amino acids were introduced

at each complementarity-determining region residue, resulting in the expression of 2,336 unique clones. Multiple clones displaying 2- to 13-fold improved affinity were identified. Subsequent expression and screening of a library of 256 combinatorial variants of the optimal mutations identified from the primary libraries resulted in the identification of multiple clones displaying greater than 50-fold enhanced affinity. These variants inhibited ligand binding to receptor more potently as demonstrated by inhibition of cell adhesion and ligand competition assays. Because of the limited mutagenesis and combinatorial approach, **Vitaxin** variants with enhanced affinity were identified rapidly and required the synthesis of only 2,592 unique variants. The use of such small focused libraries obviates the need for phage affinity selection approaches typically used, permitting the use of functional assays and the engineering of proteins expressed in mammalian cell culture.

```
? s lm609 or vitaxin

            220  LM609
             57  VITAXIN
      S4    271  LM609 OR VITAXIN
? ds

Set      Items   Description
S1          23   E2-E5
S2           2   S1 AND (LM609 OR VITAXIN)
S3           2   RD S2 (unique items)
S4         271   LM609 OR VITAXIN
```